Iovance Biotherapeutics (IOVA) Competitors $1.76 -0.16 (-8.12%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.01 (+0.28%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. MLTX, IMVT, HCM, AMRX, MIRM, OGN, APLS, DNLI, VCEL, and AAPGShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. MoonLake Immunotherapeutics Immunovant HUTCHMED Amneal Pharmaceuticals Mirum Pharmaceuticals Organon & Co. Apellis Pharmaceuticals Denali Therapeutics Vericel Ascentage Pharma Group International Iovance Biotherapeutics (NASDAQ:IOVA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations. Does the media favor IOVA or MLTX? In the previous week, Iovance Biotherapeutics had 24 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 52 mentions for Iovance Biotherapeutics and 28 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.06 beat Iovance Biotherapeutics' score of 0.08 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 6 Very Positive mention(s) 7 Positive mention(s) 35 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 11 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, IOVA or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$212.68M2.80-$444.04M-$1.24-1.44MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$2.30-17.24 Do analysts rate IOVA or MLTX? Iovance Biotherapeutics presently has a consensus target price of $13.30, suggesting a potential upside of 645.10%. MoonLake Immunotherapeutics has a consensus target price of $78.71, suggesting a potential upside of 98.54%. Given Iovance Biotherapeutics' higher probable upside, equities research analysts plainly believe Iovance Biotherapeutics is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IOVA or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -451.25%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-451.25% -58.43% -45.48% MoonLake Immunotherapeutics N/A -15.54%-15.09% Do insiders & institutionals have more ownership in IOVA or MLTX? 77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 12.1% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, IOVA or MLTX? Iovance Biotherapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Does the MarketBeat Community believe in IOVA or MLTX? Iovance Biotherapeutics received 505 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 82.76% of users gave MoonLake Immunotherapeutics an outperform vote while only 74.16% of users gave Iovance Biotherapeutics an outperform vote. CompanyUnderperformOutperformIovance BiotherapeuticsOutperform Votes57774.16% Underperform Votes20125.84% MoonLake ImmunotherapeuticsOutperform Votes7282.76% Underperform Votes1517.24% SummaryMoonLake Immunotherapeutics beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$599.41M$2.94B$5.40B$8.49BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-1.2030.9526.7119.93Price / Sales2.80410.01395.44119.84Price / CashN/A168.6838.2534.62Price / Book0.783.316.854.59Net Income-$444.04M-$72.17M$3.23B$248.19M7 Day Performance4.69%6.36%5.35%2.21%1 Month Performance-42.05%9.80%13.31%16.23%1 Year Performance-82.70%-27.03%17.58%8.00% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.4368 of 5 stars$1.76-8.1%$13.30+657.8%-81.5%$586.05M$212.68M-1.18500Trending NewsGap DownMLTXMoonLake Immunotherapeutics3.2957 of 5 stars$40.36+4.9%$80.50+99.5%+4.2%$2.59BN/A-31.422Positive NewsAnalyst UpgradeGap UpIMVTImmunovant2.6994 of 5 stars$14.52+3.5%$38.33+164.1%-51.4%$2.47BN/A-5.54120News CoveragePositive NewsGap UpHCMHUTCHMED2.271 of 5 stars$13.98-1.6%$19.00+35.9%-33.9%$2.42B$630.20M0.001,760Positive NewsGap DownAMRXAmneal Pharmaceuticals3.2515 of 5 stars$7.59+2.4%$11.50+51.6%+10.3%$2.35B$2.83B-11.157,600MIRMMirum Pharmaceuticals4.0809 of 5 stars$45.86+3.6%$59.00+28.7%+79.2%$2.28B$379.25M-22.77140News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionOGNOrganon & Co.4.7544 of 5 stars$8.62-0.9%$18.00+108.9%-59.8%$2.24B$6.29B2.5910,000High Trading VolumeAPLSApellis Pharmaceuticals4.1715 of 5 stars$17.46+0.9%$41.37+136.9%-57.2%$2.20B$781.37M-8.62770Gap UpDNLIDenali Therapeutics4.4205 of 5 stars$14.82+3.1%$33.79+127.9%-29.0%$2.15B$330.53M-5.37430Analyst ForecastVCELVericel2.5508 of 5 stars$42.66+2.2%$60.86+42.7%-14.9%$2.14B$238.54M711.02300Positive NewsAAPGAscentage Pharma Group InternationalN/A$24.29-0.1%N/AN/A$2.11B$980.65M0.00600Positive NewsGap Up Related Companies and Tools Related Companies MoonLake Immunotherapeutics Competitors Immunovant Competitors HUTCHMED Competitors Amneal Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Organon & Co. Competitors Apellis Pharmaceuticals Competitors Denali Therapeutics Competitors Vericel Competitors Ascentage Pharma Group International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IOVA Stock Free IOVA Stock Alerts